The early systemic prophylaxis of infection after stroke study: A randomized clinical trial

Stroke

Volumn 36, Issue 7, 2005, Pages 1495-1500

  Chamorro, Ángel ^a,b   Horcajada, J P ^b   Obach, V ^a   Vargas, M ^b   Revilla, M ^a   Torres, F ^b   Cervera, A ^a   Planas, A M ^a   Mensa, J ^b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Randomized controlled trials; Stroke

Indexed keywords

ANTIBIOTIC AGENT; LEVOFLOXACIN;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CALCULATION; CLINICAL FEATURE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INFECTION; INFECTION RISK; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; STROKE; TREATMENT OUTCOME;

AGED; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BODY TEMPERATURE; BRAIN; BRAIN ISCHEMIA; C-REACTIVE PROTEIN; CEREBROVASCULAR ACCIDENT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFECTION; ISCHEMIA; LEUKOCYTES; MALE; MIDDLE AGED; ODDS RATIO; OFLOXACIN; PLACEBOS; RISK; TIME FACTORS; TREATMENT OUTCOME;

EID: 22044450461     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000170644.15504.49     Document Type: Article

References (32)

1. Johnston KC, Li JY, Lyden PD, Hanson SK, Feasby TE, Adams RJ, Faught RE Jr, Haley EC Jr; for the RANTTAS Investigators. Medical and neurological complications of ischemic stroke: experience from the RANTTAS trial. Stroke. 1998;29:447-453.
2. Grau AJ, Buggle F, Schnitzler P, Spiel M, Lichy C, Hacke W. Fever and infection early after ischemic stroke. J Neurol Sci. 1999;171:115-120.
3. Langhorne P, Stott DJ, Robertson L, MacDonald J, Jones L, McAlpine C, Dick F, Taylor GS, Murray G. Medical complications after stroke: a multicenter study. Stroke. 2000;31:1223-1229.
4. Weimar C, Roth MP, Zillessen G, Glahn J, Wimmer ML, Busse O, Haberl RL, Diener HC; for the German Stroke Date Bank Collaborators. Complications following acute ischemic stroke. Eur Neurol. 2002;48: 133-140.
5. Davenport RJ, Dennis MS, Wellwood I, Warlow CP. Complications after acute stroke. Stroke. 1996;27:415-420.
6. Castillo J, Dávalos A, Marrugat J, Nova M. Timing for fever-related brain damage in acute ischemic stroke. Stroke. 1998;29:2455-2460.
7. Hindfeldt B. The prognostic significance of subfebrility and fever in ischemic cerebral infarction. Acta Neurol Scand. 1976;53:72-79.
8. Azzimondi G, Bassein L, Nonino F, Fiorani L, Vignatelli L, Re G, D'Alessandro R. Fever in acute stroke worsens prognosis. A prospective study. Stroke. 1995;26:2040-2043.
9. Nakagawa T, Sekizawa K, Arai H, Kikuchi R, Manabe K, Sasaki H. High incidence of pneumonia in elderly patients with basal ganglia infarction. Arch Intern Med. 1997;157:321-324.
10. Lindsberg PJ, Grau AJ. Inflammation and infection as risk factors for ischemic stroke. Stroke. 2003;34:2518-2532.
11. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351:2611-2618.
12. Ginsberg MD, Busto R. Combating hyperthermia in acute stroke: a significant clinical concern. Stroke. 1998;29:529-534.
13. Kasner SE, Wein T, Piriyawat P, Villar-Cordova CE, Chalela JA, Krieger DW, Morgenstern LB, Kimmel SE, Grotta JC. Acetaminophen for altering body temperature in acute stroke. A randomized clinical trial. Stroke. 2002;33:130.
14. Koennecke HC, Leistner S. Prophylactic antipyretic treatment with acetaminophen in acute ischemic stroke: a pilot study. Neurology. 2001;26: 57:2301-2303.
15. The European Stroke Initiative Executive Committee and the EUSI Writing Committee European Stroke Initiative Recommendations for Stroke Management-Update 2003. Cerebrovasc Dis. 2003;16:311-337.
16. Adams HP Jr., Adams RJ, Brott T, del Zoppo GJ, Furlan A, Goldstein LB, Grubb RL, Higashida R, Kidwell C, Kwiatkowski TG, Marler JR, Hademenos GJ; for the Stroke Council of the Am Stroke Association. Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the Am Stroke Association. Stroke. 2003;34:1056-1083.
17. Warlow C, Sudlow C, Dennis M, Wardlaw J, Sandercock P. Stroke. Lancet. 2003;362:1211-1214.
18. Prass K, Meisel C, Höflich C, Victorov I, Wolf T, Megow D, Halle E, Volk HD, Dirnagl U, Meisel A. Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation: reversal by post-stroke Th1-like immunostimulation. J Exp Med. 2003;198:725-736.
19. Meisel C, Prass K, Braun J, Braun J, Halle E, Wolf T, Ruscher K, Victorov IV, Priller J, Dirnagl U, Volk HD, Meisel A. Preventive anti-bacterial treatment improves the general medical and neurological outcome in a mouse model of stroke. Stroke. 2004;35:2-6.
20. Xu L, Fagan SC, Waller JL, Edwards D, Borlongan CV, Zheng J, Hill WD, Feuerstein G, Hess DC. Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats. BMC Neurology. 2004;4:7.
21. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd. Classification of subtype of acute stroke. Definitions for use in a multicemer clinical trial. Stroke. 1993;24:35-41.
22. Linfante I, Llinas RH, Selim M, Chaves C, Kumar S, Parker RA, Caplan LR, Schlaug G. Clinical and vascular outcome in internal carotid artery versus middle cerebral artery occlusions after intravenous tissue plasminogen activator. Stroke. 2002;33:2066-2071.
23. Wimer SM, Garrison MW. Levoflosacin: a therapeutic review. Clin Ther. 1998;20:1049-1070.
24. Carbon C. Comparison of side effects of levofloxacin versus other fluoroquinolones. Chemotherapy. 2001;47:9-14.
25. Jongbloed L. Prediction of function after stroke: a critical review. Stroke. 1986;17:765-776.
26. German Stroke Study Collaboration. Predicting outcome after acute ischemic stroke. An external validation of prognostic models. Neurology. 2004;62:581-585.
27. Audebert HJ, Rott MM, Eck T, Haberl RL. Systemic Inflammatory response depends on initial stroke severity but is attenuated by successful thrombolysis. Stroke. 2004;35:2128-2133.
28. Muir KW, Weir CJ, Alwan W, Squire IB, Lees KR. C-reactive protein and outcome after ischemic stroke. Stroke. 1999;30:981-985.
29. Stroke Unit Trialists' Collaboration. Collaborative systematic review of the randomised trials of organised inpatient (stroke unit) care after stroke. BMJ. 1997;314:1151-1159.
30. Schmuck G, Schurmann A, Schluter G. Determination of the excitatory potencies of fluoroquinolones in the central nervous system by an in vitro model. Antimicrob Agents Chemother. 1998;42:1831-1836.
31. Dodd PR, Davies LP, Watson WE, Nielsen B, Dyer JA, Wong LS, Johnston GA. Neurochemical studies on quinolone antibiotics: effects on glutamate, GABA and adenosine systems in mammalian CNS. Pharmacol Toxicol. 1989;64:404-411.
32. Kalra L, Yu G, Wilson K, Roots P. Medical complications during stroke rehabilitation. Stroke. 1995;26:990-994.